Vantage Data Centers Enters London Market With £500 Million Investment
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into London with the development of a 48MW £500 million campus. In addition, the company has opened a second 40MW data center on its existing Cardiff campus.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005323/en/
Vantage Data Centers’ LHR1 campus will include 48MW of IT capacity across two facilities. (Photo: Business Wire)
Situated on nearly five acres (two hectares) in the PowerGate neighborhood of North Acton, an established data center community in the northwest part of the city, Vantage’s London campus will total 430,000 square feet (40,000 square meters) across two 24MW multi-story data centers once fully developed. The first facility will open its doors to hyperscale customers and cloud providers in late 2024, which will mark Vantage’s 11th campus in EMEA.
“Vantage has experienced rapid growth over the past three years as we continue developing state-of-the-art data center campuses across EMEA,” said Antoine Boniface, president, EMEA at Vantage Data Centers. “With London being one of the largest data center markets in the world, this expansion further solidifies Vantage’s role at the forefront of the digital infrastructure revolution. With relatively little inventory available in London and requirements on the rise, we are ideally positioned to deliver for our customers.”
London is the largest of the FLAP (Frankfurt, London, Amsterdam and Paris) data center markets, buoyed by the U.K.’s leadership in public cloud infrastructure adoption. Findings from Structure Research indicate that hyperscale data center offerings currently account for 48% of the London market, which is projected to grow to 66% by 2027, making this a key time for Vantage to enter the arena.
“The continuing demand for data centers in London offers a prime opportunity for Vantage Data Centers to make its entrance into the highly-coveted market,” said Tim Kay, deputy director for technology, Department for International Trade in London. “Vantage’s presence in London will play a key role in enabling leading technology enterprises with additional IT capacity to support digital transformation initiatives and cloud adoption.”
In addition to the development of its London campus, Vantage has completed the first phase (12MW) of a second 40MW facility at its growing Cardiff campus, located in Wales, the second largest data center market in the U.K. The new facility boasts one of the lowest power usage effectiveness (PUE) ratios across all of Vantage’s facilities thanks in part to its extremely energy efficient indirect evaporative free cooling system, which negates the need for compressors in the cooling cycle.
Once fully developed, the 46-acre campus (19 hectares) will include three data centers totaling 148MW across 2 million square feet (186,000 square meters). Conveniently located in the U.K.’s tech corridor near the M4 and just 100 miles (160 kilometers) from London’s urban density, the campus offers numerous connectivity options with low latency between Wales and London of less than 1.5 milliseconds. The sustainable campus operates entirely on renewable energy sources.
“We are delighted to welcome customers to our newest data center in Cardiff,” said Justin Jenkins, Vantage’s chief operating officer, Europe and president, U.K. “The significant investment Vantage is making in Wales is transforming the area into one of Europe’s leading data center hubs and a top cloud region in the U.K. This is great news for the local economy as the added capacity will attract more global companies to the region, ensuring additional work for hundreds of local contractors on site and creating new permanent job opportunities.”
In December 2021, Vantage opened a corporate office in the Farringdon district of Central London to support the company’s scaling operations across EMEA.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit http://www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005323/en/
Contact information
Press
Mark Freeman
Vantage Data Centers
mfreeman@vantage-dc.com
+1-202-680-4243
Robin Bectel
REQ for Vantage Data Centers
vdc@req.co
+1-202-936-6335
Marion Chevillotte
Vantage Data Centers
mchevillotte@vantage-dc.com
+352 691 000 551
Nigel Parker
Fulfil Communications for Vantage Data Centers
nigelp@fulfilcom.com
+44 (0) 7778 872 457
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom